Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Epidemiology, Management and Outcomes of Graves’ Disease-Real Life Data
source: Endocrine
year: 2017
authors: Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP
summary/abstract:Purpose:
Treatment options in Graves’ disease are clearly defined, but management practices and the perceptions of success are varied. The outcomes of treatment in large consecutive cohorts of Graves’ disease have not been well characterised. The study describes the epidemiology, management strategies and medium term outcomes following anti-thyroid drug treatment, radio-iodine ablation and surgery in Graves’ disease.
Methods:
All patients (n = 659) who received treatment for a new diagnosis of Graves’ disease in secondary care over a 5 year period were included with a median (interquartile range) follow-up of 42.9 (29-57.5) months.
Results:
The age adjusted incidence of adult onset Graves’ disease in Sheffield, UK was 24.8 per 100,000 per year. Excluding 35 patients lost to follow-up, 93.1% (n = 581) were controlled on anti-thyroid drug treatment. Of these, 73.6% went into remission following withdrawal of anti-thyroid drugs; 5.2% were still undergoing initial therapy; 13.3% lost control whilst on anti-thyroid drugs; and 7.9% went on to have either surgery or radio-iodine ablation whilst controlled on anti-thyroid drugs. Of the 428 patients who achieved remission, 36.7% relapsed. Of 144 patients who had radio-iodine ablation treatment, 5.6% relapsed and needed further treatment. Of 119 patients having surgery, 5.2% had long-term hypoparathyroidism and none had documented long-term recurrent laryngeal nerve palsy.
Conclusions:
In the follow-up, 39.9% of patients underwent surgery or radio-iodine ablation with little morbidity. Up to two-thirds of patients who achieved remission did not relapse. Data on effectiveness and risks of treatments for Graves’ disease presented in this study will help clinicians and patients in decision making.
DOI: 10.1007/s12020-017-1306-5
read more full text
myBinderRelated Content
-
No Need to Suffer From Double Vision With Graves’ Diseasehttps://www.youtube.com/watch?v=cQ7-Yi5t...
-
A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients With Minimally Active Grav...Context: Radioiodine is an effective an...
-
The History of Levothyroxine – The Most Prescribed Drug in the United States With Dr. James V. Hennessey from Harv...In this interview, Dr. Hennessey describ...
-
Endocrinology in Pregnancy: Pregnancy and the Incidence, Diagnosing and Therapy of Graves’ DiseaseThyroid hormones are essential developme...
-
External Validation of the GREAT Score to Predict Relapse Risk in Graves’ Disease: Results from a Multicenter,...Context: First-line treatment in Graves...
-
Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves HyperthyroidismContext: Supplemental selenium (Se) may...
-
Evaluation of Patients With Graves’ Disease: Pediatric Thyroid Center at CHOP (Part 3 of 9)https://www.youtube.com/watch?v=DUhCB986...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google